Physician profile
Michael P Carson
NPI 1477999282
$14,340.45
in general payments reported to CMS, 2019-2025
43 companies · $1,867 in 2025
The $1,867 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,828 · 2020: $2,033 · 2021: $2,352 · 2022: $2,229 · 2023: $2,270 · 2024: $1,761 · 2025: $1,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,886 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,886.25 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,721.33 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $1,502.34 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,379.19 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $1,315.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,144.51 | 2019-2025 | |
| Amgen INC. | $1,126.26 | 2019-2025 | Otezla, Repatha, Repatha |
| Allergan, INC. | $696.52 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $683.10 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $555.03 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $528.75 | 2019-2025 | Jardiance, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $424.24 | 2019-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $422.34 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $401.41 | 2019-2025 | Belsomra, Capvaxive |
| Abbott Laboratories | $261.12 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $222.86 | 2020-2024 | Linzess |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $187.61 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Dexcom, INC. | $168.97 | 2020-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $148.14 | 2022 | |
| Eisai INC. | $125.67 | 2020-2025 | |
| Nestle Healthcare Nutrition INC. | $125.05 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $115.40 | 2023-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.83 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $108.79 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $100.60 | 2021 | |
| Astellas Pharma US INC | $94.17 | 2022-2024 | Veozah |
| Exact Sciences Corporation | $93.21 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $91.69 | 2020-2024 | |
| Esperion Therapeutics, INC. | $89.30 | 2023-2024 | Nexletol |
| Kaleo, INC. | $68.69 | 2020-2021 | |
| Sanofi Pasteur INC. | $60.91 | 2019-2021 | |
| Boston Scientific Corporation | $57.74 | 2024-2025 | Wavewriter Alpha Prime 16, Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $40.31 | 2022 | |
| Baxter Healthcare | $21.16 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $17.19 | 2024 | |
| Sumitomo Pharma America, INC. | $16.32 | 2025 | Gemtesa |
| Nevro Corp. | $16.00 | 2023 | Senza |
| Teva Pharmaceuticals USA, INC. | $15.75 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.16 | 2024 | Quviviq |
| Currax Pharmaceuticals LLC | $13.85 | 2023 | Contrave, Onzetra Xsail |
| Nalpropion Pharmaceuticals LLC | $13.67 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.44 | 2023 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $13.27 | 2021 | |
| Axsome Therapeutics, INC. | $12.90 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.